$235 Million is the total value of CHI Advisors LLC's 22 reported holdings in Q1 2022. The portfolio turnover from Q4 2021 to Q1 2022 was 10.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| RXDX | Sell | PROMETHEUS BIOSCIENCES INC | $59,853,000 | -13.6% | 1,585,096 | -9.5% | 25.45% | +10.7% |
| RPTX | Buy | REPARE THERAPEUTICS INC | $36,755,000 | -21.2% | 2,581,097 | +16.7% | 15.63% | +0.9% |
| CGEM | Buy | CULLINAN ONCOLOGY INC | $28,824,000 | -24.6% | 2,753,047 | +11.2% | 12.26% | -3.4% |
| PLRX | Buy | PLIANT THERAPEUTICS INC | $18,629,000 | -46.3% | 2,657,457 | +3.4% | 7.92% | -31.2% |
| VECT | Buy | VECTIVBIO HLDG AG | $14,527,000 | +10.6% | 3,084,310 | +15.3% | 6.18% | +41.7% |
| New | 2SEVENTY BIO INC | $13,984,000 | – | 819,672 | +100.0% | 5.95% | – | |
| OMEGA THERAPEUTICS INC | $6,589,000 | -44.9% | 1,055,882 | 0.0% | 2.80% | -29.4% | ||
| LRMR | LARIMAR THERAPEUTICS INC | $6,136,000 | -62.5% | 1,515,148 | 0.0% | 2.61% | -51.9% | |
| FRLN | Buy | FREELINE THERAPEUTICS HLDGSsponsored ads | $5,446,000 | +46.6% | 4,862,319 | +159.1% | 2.32% | +87.8% |
| KZR | Buy | KEZAR LIFE SCIENCES INC | $5,229,000 | +14.9% | 314,612 | +15.6% | 2.22% | +47.2% |
| IKNA | Sell | IKENA ONCOLOGY INC | $4,970,000 | -51.4% | 814,755 | -0.0% | 2.11% | -37.7% |
| ONCR | Buy | ONCORUS INC | $4,303,000 | -61.2% | 2,417,436 | +14.7% | 1.83% | -50.4% |
| AKUS | AKOUOS INC | $3,972,000 | -44.1% | 836,120 | 0.0% | 1.69% | -28.4% | |
| CMPX | Sell | COMPASS THERAPEUTICS INC | $3,877,000 | -59.6% | 2,829,712 | -6.4% | 1.65% | -48.2% |
| ORTX | Sell | ORCHARD THERAPEUTICS PLCads | $3,779,000 | -55.6% | 5,307,751 | -17.7% | 1.61% | -43.1% |
| GTHX | Buy | G1 THERAPEUTICS INC | $3,714,000 | +58.2% | 488,635 | +112.4% | 1.58% | +102.7% |
| INZY | INOZYME PHARMA INC | $3,649,000 | -40.0% | 892,057 | 0.0% | 1.55% | -23.1% | |
| KROS | Buy | KEROS THERAPEUTICS INC | $3,384,000 | +230.1% | 62,229 | +255.2% | 1.44% | +323.2% |
| CRVS | Buy | CORVUS PHARMACEUTICALS INC | $2,793,000 | +189.7% | 1,703,137 | +325.8% | 1.19% | +271.2% |
| OVID | Buy | OVID THERAPEUTICS INC | $2,678,000 | +108.6% | 852,888 | +113.2% | 1.14% | +167.4% |
| DTIL | PRECISION BIOSCIENCES INC | $1,868,000 | -58.4% | 606,629 | 0.0% | 0.79% | -46.7% | |
| XBI | New | SPDR SER TRput | $206,000 | – | 222,500 | +100.0% | 0.09% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-05-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| PRECISION BIOSCIENCES INC | 17 | Q3 2023 | 13.4% |
| OVID THERAPEUTICS INC | 17 | Q3 2023 | 5.8% |
| CORVUS PHARMACEUTICALS INC | 16 | Q2 2023 | 1.8% |
| KEZAR LIFE SCIENCES INC | 15 | Q1 2023 | 5.8% |
| PLIANT THERAPEUTICS INC | 14 | Q3 2023 | 29.2% |
| REPARE THERAPEUTICS INC | 14 | Q3 2023 | 30.3% |
| ORCHARD THERAPEUTICS PLC | 14 | Q4 2022 | 52.6% |
| LARIMAR THERAPEUTICS INC | 14 | Q3 2023 | 9.1% |
| KEROS THERAPEUTICS INC | 14 | Q3 2023 | 8.6% |
| INOZYME PHARMA INC | 13 | Q3 2023 | 9.4% |
View CHI Advisors LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Corvus Pharmaceuticals, Inc. | February 13, 2023 | 2,384,402 | 5.1% |
| Cullinan Oncology, Inc. | February 13, 2023 | 3,317,544 | 7.2% |
| Freeline Therapeutics Holdings plc | February 13, 2023 | 4,814,419 | 7.4% |
| Inozyme Pharma, Inc. | February 13, 2023 | 2,204,876 | 5.5% |
| Larimar Therapeutics, Inc. | February 13, 2023 | 3,473,366 | 8.0% |
| Oncorus, Inc. | February 13, 2023 | 2,367,436 | 9.1% |
| Orchard Therapeutics plc | February 13, 2023 | 7,987,396 | 6.3% |
| PLIANT THERAPEUTICS, INC. | February 13, 2023 | 3,199,892 | 6.6% |
| Repare Therapeutics Inc. | February 13, 2023 | 2,800,126 | 6.7% |
| VectivBio Holding AG | February 13, 2023 | 5,492,893 | 8.8% |
View CHI Advisors LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2023-11-13 |
| 13F-HR/A | 2023-08-22 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-11 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
View CHI Advisors LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.